Market capitalization | $823.73m |
Enterprise Value | $895.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.65 |
P/S ratio (TTM) P/S ratio | 3.36 |
P/B ratio (TTM) P/B ratio | 5.91 |
Revenue growth (TTM) Revenue growth | 18.16% |
Revenue (TTM) Revenue | $245.00m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Paragon 28 forecast:
7 Analysts have issued a Paragon 28 forecast:
Sep '24 |
+/-
%
|
||
Revenue | 245 245 |
18%
18%
|
|
Gross Profit | 157 157 |
2%
2%
|
|
EBITDA | -35 -35 |
73%
73%
|
EBIT (Operating Income) EBIT | -54 -54 |
54%
54%
|
Net Profit | -73 -73 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.
Head office | United States |
CEO | Albert DaCosta |
Employees | 574 |
Founded | 2010 |
Website | www.paragon28.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.